Related references
Note: Only part of the references are listed.Prediction of Cancer Incidence and Mortality in Korea, 2020
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2020)
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells
Laurence Booth et al.
CANCER BIOLOGY & THERAPY (2018)
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Hyoung Kim et al.
CLINICAL CANCER RESEARCH (2017)
Targeting DNA repair and replication stress in the treatment of ovarian cancer
Junko Murai
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
Ethan Brill et al.
ONCOTARGET (2017)
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2016)
DNA damage response - A double-edged sword in cancer prevention and cancer therapy
Hui Tian et al.
CANCER LETTERS (2015)
ATR inhibition preferentially targets homologous recombination-deficient tumor cells
M. Krajewska et al.
ONCOGENE (2015)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
The consequences of Rad51 overexpression for normal and tumor cells
Hannah L. Klein
DNA REPAIR (2008)
The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
E. M. Bahassi et al.
ONCOGENE (2008)
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics
Zehan Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
CS Sorensen et al.
NATURE CELL BIOLOGY (2005)
Share Paper
